Cydar Medical today announced that Alastair Harvey has been appointed in the newly created position of chief commercial officer, reporting to chief executive officer Paul Mussenden.
The new role reflects the company’s customer-centric focus during a stage of growth and the accelerating adoption by hospitals of its solution for endovascular surgery, a press release notes.
Harvey will be responsible for the development and execution of the company’s overall commercial strategy, covering product sales and marketing, customer onboarding, as well as the company’s analytics and platform strategies. Additionally, he will be responsible for further developing the company’s existing commercial partnerships, as well securing new ones to further expand Cydar Medical’s integrated offering of intelligent healthcare solutions.
Harvey has more than 20 years’ experience of delivering business growth for seed, start-up and small- and medium-sized enterprise (SME) organisations. He is a specialist in defining and executing successful go-to-market strategies and in the commercialisation of disruptive artificial intelligence (AI) technologies through Software as a Service and Platform as a Service models, in order to drive revenue growth.
He has held several commercial leadership roles during his career, including as chief commercial officer for Cortexica AI Vision Systems, a world leader in computer vision and machine learning which was ultimately sold to Zebra Technologies. He has also worked for Sia Partners as head of artificial intelligence, associate partner, growth innovation, for Advertima.com as managing director, growth and innovation, and most recently as chief commercial officer at Action.ai.
“I am pleased to be joining Cydar Medical at such a pivotal time in the company’s evolution,” Harvey said. “I plan to leverage my commercial expertise and market knowledge to further Cydar’s development and accelerate value creation. I very much look forward to working closely with Paul and the wider team to grow Cydar’s platform, strengthen our partnerships, and bring cutting-edge, AI-enhanced surgical tools to clinicians.”
Mussenden added: “We are delighted to be welcoming Alastair to the company. He brings leading sector knowledge and a track record of success in creating and pursuing commercial opportunities. His experience is very complementary to that of the existing Cydar Medical team and reflects our goal of building our capabilities to enable us to deliver on our ambitious growth plans”.
